Bayer HealthCare and Maxygen (MAXY) Enter Hematology Agreement
Tweet Send to a FriendGet Alerts MAXY Hot Sheet
Trade MAXY Now!
Bayer HealthCare announced the acquisition of Maxygen's (NASDAQ: MAXY) hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII. The lead therapeutic candidate is expected to enter Phase 1 clinical testing in the third quarter of 2008.
The total transaction is valued at $90 million upfront with a final, potential milestone payment of $30 million. This agreement also includes a license to use Maxygen’s MolecularBreedin technology, a novel research platform, for exploiting gene targets.
The total transaction is valued at $90 million upfront with a final, potential milestone payment of $30 million. This agreement also includes a license to use Maxygen’s MolecularBreedin technology, a novel research platform, for exploiting gene targets.
You May Also Be Interested In
- UPDATE: Viropharma, Inc. (VPHM) Said to Attract Acquisition Interest - Reuters
- Zynga (ZNGA) Gains More Real-Money Talent with Latest Purchase
- Amarin (AMRN) Vascepa sNDA Set for Oct. 16, 2013, According to FDA
Create E-mail Alert Related Categories
FDA, Mergers and Acquisitions
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
